What is the clinical evidence from this study?

Study design: Review. Population: Cardiovascular Disease. Intervention: Clinical pharmacy services.

What question did this study set out to answer?

To review the clinical training, practice models, and evidence base for clinical pharmacists in cardiovascular care, while evaluating structural barriers to their service expansion.

May 19, 2026Journal of the American College of Cardiology

The Role of the Clinical Pharmacist in the Care of Patients With Cardiovascular Disease

View Full Paper

Ask AI

Bookmark

Key result

Clinical pharmacists improve cardiovascular care through medication optimization, adverse event prevention, and transitional support.

Why the study?

Does the integration of clinical pharmacists in team-based cardiovascular care improve patient outcomes and medication optimization?

Population

Patients with cardiovascular disease

Design

Review

Authors

SDSteven P. DunnUniversity of Virginia KBKim K. BirtcherPreventive Cardiology CBC. BeaversUniversity of Kansas

Discussion

Member takes

Implication

Integration of clinical pharmacists into cardiovascular care teams optimizes medication use and improves transitional care, though policy and compensation barriers remain.

Key Points

To review the clinical training, practice models, and evidence base for clinical pharmacists in cardiovascular care, while evaluating structural barriers to their service expansion.
Reviewed literature and summarized selected systematic reviews and meta-analyses assessing the efficacy of clinical pharmacy interventions across inpatient and ambulatory settings.
Synthesized Joint Council perspectives from the American College of Cardiology on pharmacist training, credentialing, and multi-setting care delivery models.
Clinical pharmacy interventions significantly enhance outcomes through medication therapy optimization, reduction of adverse drug events, structured medication reconciliation, and patient self-management education.
Broad implementation and scalability of clinical pharmacy services remain constrained by existing legislative, health policy, and reimbursement limitations.

Structured PICO

Does the integration of clinical pharmacists in team-based cardiovascular care improve patient outcomes and medication optimization?

Population

Patients with cardiovascular disease

Intervention

Clinical pharmacist services integrated into team-based cardiovascular care

Outcome

Optimization of drug use, avoidance of adverse drug events, and transitional care activities

Integration of clinical pharmacists into cardiovascular care teams optimizes medication use and improves transitional care, though policy and compensation barriers remain.

Limitations

Expansion of clinical pharmacy services is often impeded by policy, legislation, and compensation barriers.

Cite This Study

Dunn et al. (2015) conducted a review in Cardiovascular Disease. Clinical pharmacy services was evaluated. Clinical pharmacists have a substantial effect in inpatient and ambulatory settings through optimization of drug use, avoidance of adverse drug events, and transitional care activities.

synapsesocial.com/papers/6a0c7f671d219e48eaef4d0a https://doi.org/10.1016/j.jacc.2015.09.025

View Full Paper

Ask AI

Bookmark

Implication

Integration of clinical pharmacists into cardiovascular care teams optimizes medication use and improves transitional care, though policy and compensation barriers remain.

The Role of the Clinical Pharmacist in the Care of Patients With Cardiovascular Disease

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

The Role of the Clinical Pharmacist in the Care of Patients With Cardiovascular Disease

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider